Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration

Saumya Ramanathan, Stacy Mazzalupo, Scott A Boitano, William "Bill" Montfort

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Nitric oxide (NO) regulates cardiovascular hemostasis by binding to soluble guanylyl cyclase (sGC), leading to cGMP production, reduced cytosolic calcium concentration ([Ca 2+] i), and vasorelaxation. Thrombospondin-1 (TSP-1), a secreted matricellular protein, was recently discovered to inhibit NO signaling and sGC activity. Inhibition of sGC requires binding to cell-surface receptor CD47. Here, we show that a TSP-1 C-terminal fragment (E3CaG1) readily inhibits sGC in Jurkat T cells and that inhibition requires an increase in [Ca 2+] i. Using flow cytometry, we show that E3CaG1 binds directly to CD47 on the surface of Jurkat T cells. Using digital imaging microscopy on live cells, we further show that E3CaG1 binding results in a substantial increase in [Ca 2+] i, up to 300 nM. Addition of angiotensin II, a potent vasoconstrictor known to increase [Ca 2+] i, also strongly inhibits sGC activity. sGC isolated from calcium-treated cells or from cell-free lysates supplemented with Ca 2+ remains inhibited, while addition of kinase inhibitor staurosporine prevents inhibition, indicating inhibition is likely due to phosphorylation. Inhibition is through an increase in K m for GTP, which rises to 834 μM for the NO-stimulated protein, a 13-fold increase over the uninhibited protein. Compounds YC-1 and BAY 41-2272, allosteric stimulators of sGC that are of interest for treating hypertension, overcome E3CaG1-mediated inhibition of NO-ligated sGC. Taken together, these data suggest that sGC not only lowers [Ca 2+] i in response to NO, inducing vasodilation, but also is inhibited by high [Ca 2+] i, providing a fine balance between signals for vasodilation and vasoconstriction.

Original languageEnglish (US)
Pages (from-to)7787-7799
Number of pages13
JournalBiochemistry
Volume50
Issue number36
DOIs
StatePublished - Sep 13 2011

Fingerprint

Thrombospondin 1
Guanylate Cyclase
Angiotensin II
Calcium
Nitric Oxide
Vasodilation
Jurkat Cells
T-cells
T-Lymphocytes
Soluble Guanylyl Cyclase
Phosphorylation
Proteins
Staurosporine
Flow cytometry
Cell Surface Receptors
Vasoconstrictor Agents
Guanosine Triphosphate
Vasoconstriction
Hemostasis
Microscopy

ASJC Scopus subject areas

  • Biochemistry

Cite this

Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. / Ramanathan, Saumya; Mazzalupo, Stacy; Boitano, Scott A; Montfort, William "Bill".

In: Biochemistry, Vol. 50, No. 36, 13.09.2011, p. 7787-7799.

Research output: Contribution to journalArticle

@article{0f5d617edcf24000a1d1ea8f2cd035b6,
title = "Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration",
abstract = "Nitric oxide (NO) regulates cardiovascular hemostasis by binding to soluble guanylyl cyclase (sGC), leading to cGMP production, reduced cytosolic calcium concentration ([Ca 2+] i), and vasorelaxation. Thrombospondin-1 (TSP-1), a secreted matricellular protein, was recently discovered to inhibit NO signaling and sGC activity. Inhibition of sGC requires binding to cell-surface receptor CD47. Here, we show that a TSP-1 C-terminal fragment (E3CaG1) readily inhibits sGC in Jurkat T cells and that inhibition requires an increase in [Ca 2+] i. Using flow cytometry, we show that E3CaG1 binds directly to CD47 on the surface of Jurkat T cells. Using digital imaging microscopy on live cells, we further show that E3CaG1 binding results in a substantial increase in [Ca 2+] i, up to 300 nM. Addition of angiotensin II, a potent vasoconstrictor known to increase [Ca 2+] i, also strongly inhibits sGC activity. sGC isolated from calcium-treated cells or from cell-free lysates supplemented with Ca 2+ remains inhibited, while addition of kinase inhibitor staurosporine prevents inhibition, indicating inhibition is likely due to phosphorylation. Inhibition is through an increase in K m for GTP, which rises to 834 μM for the NO-stimulated protein, a 13-fold increase over the uninhibited protein. Compounds YC-1 and BAY 41-2272, allosteric stimulators of sGC that are of interest for treating hypertension, overcome E3CaG1-mediated inhibition of NO-ligated sGC. Taken together, these data suggest that sGC not only lowers [Ca 2+] i in response to NO, inducing vasodilation, but also is inhibited by high [Ca 2+] i, providing a fine balance between signals for vasodilation and vasoconstriction.",
author = "Saumya Ramanathan and Stacy Mazzalupo and Boitano, {Scott A} and Montfort, {William {"}Bill{"}}",
year = "2011",
month = "9",
day = "13",
doi = "10.1021/bi201060c",
language = "English (US)",
volume = "50",
pages = "7787--7799",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "36",

}

TY - JOUR

T1 - Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration

AU - Ramanathan, Saumya

AU - Mazzalupo, Stacy

AU - Boitano, Scott A

AU - Montfort, William "Bill"

PY - 2011/9/13

Y1 - 2011/9/13

N2 - Nitric oxide (NO) regulates cardiovascular hemostasis by binding to soluble guanylyl cyclase (sGC), leading to cGMP production, reduced cytosolic calcium concentration ([Ca 2+] i), and vasorelaxation. Thrombospondin-1 (TSP-1), a secreted matricellular protein, was recently discovered to inhibit NO signaling and sGC activity. Inhibition of sGC requires binding to cell-surface receptor CD47. Here, we show that a TSP-1 C-terminal fragment (E3CaG1) readily inhibits sGC in Jurkat T cells and that inhibition requires an increase in [Ca 2+] i. Using flow cytometry, we show that E3CaG1 binds directly to CD47 on the surface of Jurkat T cells. Using digital imaging microscopy on live cells, we further show that E3CaG1 binding results in a substantial increase in [Ca 2+] i, up to 300 nM. Addition of angiotensin II, a potent vasoconstrictor known to increase [Ca 2+] i, also strongly inhibits sGC activity. sGC isolated from calcium-treated cells or from cell-free lysates supplemented with Ca 2+ remains inhibited, while addition of kinase inhibitor staurosporine prevents inhibition, indicating inhibition is likely due to phosphorylation. Inhibition is through an increase in K m for GTP, which rises to 834 μM for the NO-stimulated protein, a 13-fold increase over the uninhibited protein. Compounds YC-1 and BAY 41-2272, allosteric stimulators of sGC that are of interest for treating hypertension, overcome E3CaG1-mediated inhibition of NO-ligated sGC. Taken together, these data suggest that sGC not only lowers [Ca 2+] i in response to NO, inducing vasodilation, but also is inhibited by high [Ca 2+] i, providing a fine balance between signals for vasodilation and vasoconstriction.

AB - Nitric oxide (NO) regulates cardiovascular hemostasis by binding to soluble guanylyl cyclase (sGC), leading to cGMP production, reduced cytosolic calcium concentration ([Ca 2+] i), and vasorelaxation. Thrombospondin-1 (TSP-1), a secreted matricellular protein, was recently discovered to inhibit NO signaling and sGC activity. Inhibition of sGC requires binding to cell-surface receptor CD47. Here, we show that a TSP-1 C-terminal fragment (E3CaG1) readily inhibits sGC in Jurkat T cells and that inhibition requires an increase in [Ca 2+] i. Using flow cytometry, we show that E3CaG1 binds directly to CD47 on the surface of Jurkat T cells. Using digital imaging microscopy on live cells, we further show that E3CaG1 binding results in a substantial increase in [Ca 2+] i, up to 300 nM. Addition of angiotensin II, a potent vasoconstrictor known to increase [Ca 2+] i, also strongly inhibits sGC activity. sGC isolated from calcium-treated cells or from cell-free lysates supplemented with Ca 2+ remains inhibited, while addition of kinase inhibitor staurosporine prevents inhibition, indicating inhibition is likely due to phosphorylation. Inhibition is through an increase in K m for GTP, which rises to 834 μM for the NO-stimulated protein, a 13-fold increase over the uninhibited protein. Compounds YC-1 and BAY 41-2272, allosteric stimulators of sGC that are of interest for treating hypertension, overcome E3CaG1-mediated inhibition of NO-ligated sGC. Taken together, these data suggest that sGC not only lowers [Ca 2+] i in response to NO, inducing vasodilation, but also is inhibited by high [Ca 2+] i, providing a fine balance between signals for vasodilation and vasoconstriction.

UR - http://www.scopus.com/inward/record.url?scp=80052479984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052479984&partnerID=8YFLogxK

U2 - 10.1021/bi201060c

DO - 10.1021/bi201060c

M3 - Article

C2 - 21823650

AN - SCOPUS:80052479984

VL - 50

SP - 7787

EP - 7799

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 36

ER -